(Q36986043)

17 August 2017

1 reference

title

Alefacept for the treatment of psoriasis and other dermatologic diseases (English)

1 reference

17 August 2017

1

1 reference

17 August 2017

Kavita Menon

2

1 reference

17 August 2017

language of work or name

1 reference

1 July 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

20

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

270-276

1 reference

Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Alefacept: an expert review concerning the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Alefacept: a safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Ecthyma gangrenosum and septic shock syndrome secondary to Chromobacterium violaceum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Tinea profunda cysticum caused by Trichophyton rubrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Cutaneous adverse events of biological therapy for psoriasis: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

New treatments for psoriasis: which biologic is best?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00140.X

10.1111/J.1529-8019.2007.00140.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference